Briacell Therapeutics - 30BCTXZPreferred / convertible
13F holders, Q1 2026 (March 31)4holders
0new positions
0sold out
$0.14avg. 13F price*
At the end of Q1 2026, 4 institutions reported holding Briacell Therapeutics - 30 (BCTXZ) in their 13F filings, unchanged from Q4 2025. 0 opened new positions and 0 sold out. The largest holders were Empery Asset Management, LP ($93K), Heights Capital Management, Inc. ($76K) and Sabby Management, LLC ($29K).
- Company
- Briacell Therapeutics - 30
- CUSIP
- 107930117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 4,692 shares bought and 63,811 shares sold, net −59,119 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Empery Asset Management, LP | — | No change | 666,600 | $93K |
| Heights Capital Management, Inc. | — | Reduce -0.8% | 540,098 | $76K |
| Sabby Management, LLC | — | Reduce -22.3% | 206,753 | $29K |
| UBS Group AG | — | Add +93840.0% | 4,697 | $658 |
"% of holder's portfolio" is BCTXZ's weight in each manager's 13F, not the share of Briacell Therapeutics - 30 the manager owns.